April 2026 Research Update

This month, one study in children with CRMO found that using TNF inhibitors (TNFi, immune-targeting medicines) was not linked to higher complete remission rates or lower recurrence compared with not using TNFi, within that health system and follow-up. At the same time, TNFi tended to be used in children who already had more severe or complicated disease, such as spine involvement or bone damage. The safety signals reported in this study were reassuring, with only mild infections or liver test changes reported. [1]

When the researchers compared children who did and did not receive TNFi, the TNFi group had more spinal involvement, more bone destruction, and more gastrointestinal involvement, suggesting TNFi was often chosen for harder-to-control cases rather than average cases. Even with these baseline differences, the study reported similar rates of complete remission and recurrence between groups, and similar rates of mild side effects. The study also reported differences in a blood inflammation marker (IL-6) between groups, but the meaning of that difference for symptoms or long-term outcomes was not fully clear from the summary provided. [1]

For families, this study mainly adds real-world information about how TNFi are being used and what outcomes were observed in one pediatric CRMO cohort. It does not show a clear difference in remission or recurrence between TNFi and no TNFi, but it also shows that children given TNFi often had more spine involvement or bone damage to begin with, which can make simple comparisons hard. The safety information in this report may feel encouraging, but it is still based on a relatively small group and a retrospective comparison rather than a head-to-head trial. [1]

This month, a large pediatric comparison study reported that the newer EULAR/ACR classification criteria identified more children with chronic nonbacterial osteomyelitis (CNO, a related name to CRMO) than the older Bristol criteria, while keeping a similar ability to rule out common look-alike conditions. In plain terms, the newer criteria were less likely to miss CNO, including less typical presentations. The study still emphasized that expert clinical judgment is important, because some other inflammatory conditions can overlap in appearance. [2]

In 114 children diagnosed with CNO and 116 children with mimicking conditions, the EULAR/ACR criteria had higher sensitivity (97.4%) than the Bristol criteria (79.8%), while specificity was similar (81.0% vs 80.2%). This means the newer criteria, when used as a classification approach in research-style comparisons, captured a larger share of the children who truly had CNO in this cohort. The authors also noted that some basic lab patterns differed between groups (for example, elevated ESR supporting CNO and profound anemia being more common in mimicking disorders), which may help explain how clinicians think through confusing cases. [2]

For patients and caregivers, this study matters most for the diagnosis journey and for research studies that enroll people with CNO/CRMO. More sensitive criteria could mean fewer children with less typical symptoms are overlooked when researchers or specialists are deciding whether a case fits CNO/CRMO patterns. It does not replace a clinician evaluation, and the authors explicitly said clinical judgment is still needed when conditions overlap, but it helps clarify that the newer criteria may better include atypical presentations. [2]